TECH is set to report Q2 results on Feb. 4, with EPS seen at 43 cents and revenues at $292M as tariffs, NIH funding and segment shifts shape outlook.

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today ...

Techne Corporation, the Minneapolis-based biotechnology company that now does business under the “Bio-Techne” brand, recently announced that it’s investing $10 million CyVek, Inc.—and it might ...

Techne Corporation—whose longtime CEO resigned in November and protested the search process for his successor—said Monday that it has appointed a new chief executive. Techne, a Minneapolis-based maker ...

Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...

Bio-Techne Corp. failed to get shareholder approval on its executive compensation plan. While the vote is nonbinding, a no vote is rare. Only 35% of shareholders supported the plan during the ...

Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...

A congressional transaction is when any representative or senator either buys or sells an individual stock. Anyone working in Congress must file a Periodic Transaction Report to inform the public of ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

More than 600,000 times, researchers have cited Bio-Techne Corp. in academic papers as a manufacturer of tools that helped in their search for new tests and treatments. The company, Minnesota's ...

Bio-Techne Corp. closed 17.31% short of its 52-week high of $79.28, which the company reached on February 5th.